587 related articles for article (PubMed ID: 26395836)
1. Biosimilars for the management of rheumatoid arthritis: economic considerations.
Gulácsi L; Brodszky V; Baji P; Kim H; Kim SY; Cho YY; Péntek M
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S43-52. PubMed ID: 26395836
[TBL] [Abstract][Full Text] [Related]
2. The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis.
Yoo DH
Expert Rev Clin Immunol; 2014 Aug; 10(8):981-3. PubMed ID: 24961712
[TBL] [Abstract][Full Text] [Related]
3. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
Müller-Ladner U; Hong S; Oh C; Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
[TBL] [Abstract][Full Text] [Related]
4. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
Taylor P
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.
Valido A; Silva-Dinis J; Saavedra MJ; Iria I; Gonçalves J; Lopes JP; Fonseca JE
Acta Reumatol Port; 2019; 44(4):303-311. PubMed ID: 31754088
[TBL] [Abstract][Full Text] [Related]
6. CT-P13 in the treatment of rheumatoid arthritis.
Yoo DH
Expert Rev Clin Immunol; 2017 Jul; 13(7):653-666. PubMed ID: 28571501
[TBL] [Abstract][Full Text] [Related]
7. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.
Jha A; Upton A; Dunlop WC; Akehurst R
Adv Ther; 2015 Aug; 32(8):742-56. PubMed ID: 26343027
[TBL] [Abstract][Full Text] [Related]
8. Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis.
Curtis JR; Xie F; Kay J; Kallich JD
Arthritis Res Ther; 2019 Dec; 21(1):285. PubMed ID: 31831064
[TBL] [Abstract][Full Text] [Related]
9. Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.
Yoo DH; Oh C; Hong S; Park W
Expert Rev Clin Immunol; 2015; 11 Suppl 1():S15-24. PubMed ID: 26395833
[TBL] [Abstract][Full Text] [Related]
10. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
Aladul MI; Fitzpatrick RW; Chapman SR
BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues.
Lapadula G; Ferraccioli GF
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S102-6. PubMed ID: 23078880
[TBL] [Abstract][Full Text] [Related]
12. Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea.
Cho SK; Jung SY; Kim H; Song YJ; Lee K; Sung YK
J Korean Med Sci; 2021 May; 36(20):e143. PubMed ID: 34032032
[TBL] [Abstract][Full Text] [Related]
13. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries.
Brodszky V; Baji P; Balogh O; Péntek M
Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S65-71. PubMed ID: 24832837
[TBL] [Abstract][Full Text] [Related]
14. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database.
Kim J; Ha D; Song I; Park H; Lee SW; Lee EK; Shin JY
Int J Rheum Dis; 2018 Jun; 21(6):1227-1236. PubMed ID: 29667324
[TBL] [Abstract][Full Text] [Related]
15. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
Braun J; Kudrin A
Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis.
Patel D; Shelbaya A; Cheung R; Aggarwal J; Park SH; Coindreau J
Adv Ther; 2019 Aug; 36(8):2086-2095. PubMed ID: 31148057
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.
Isaacs JD; Cutolo M; Keystone EC; Park W; Braun J
J Intern Med; 2016 Jan; 279(1):41-59. PubMed ID: 26403380
[TBL] [Abstract][Full Text] [Related]
18. Of patents and patent disputes - The TNFα patent files. Part 2: Enbrel, Remicade, Cimzia and Simponi.
Storz U
Hum Antibodies; 2018 Feb; 26(2):49-61. PubMed ID: 29439320
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?
Araújo FC; Gonçalves J; Fonseca JE
Curr Rheumatol Rep; 2016 Aug; 18(8):50. PubMed ID: 27402107
[TBL] [Abstract][Full Text] [Related]
20. Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis.
Ascef BO; Almeida MO; de Medeiros Ribeiro AC; Andrade DCO; de Oliveira Júnior HA; Pereira TV; de Soárez PC
Syst Rev; 2021 Jul; 10(1):205. PubMed ID: 34274019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]